Immune checkpoint inhibitors operate by restoring the anti-tumor activity of T cells, blocking inhibitory signals on the surface of T cells—such as those in the PD-1/PD-L1 pathway—thereby boosting the efficacy of TCR-T cell therapy. Here, CD274 is linked to neoplasm.